Boehringer Ingelheim International GmbH (Emerging Leader) is classified as a rapidly emerging leader, with a focus on developing a novel GLP-1 agonist (Survodutide) in phase 3 of clinical development
Older adults considering GLP-1 medications or medical weight loss should be monitored carefully and should prioritize strength, mobility, protein intake, and functional health not just scale weight
The vasomodulatory effects of GLP-1RAs also extend to glaucoma models, although the observed outcomes differ
Action produces results, results fuel motivation, and motivation transforms identity
Over the last few years, the popularity of taking GLP-1 medications for weight loss has greatly increased
Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas